Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last1,901 to 1,920 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Treatment Group vs Control Group: Self-reported Lifetime Inhalant Use | 379 of 2,324 342 of 2,358 | 1.8 points -0.3 to 3.9 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported 30-day Inhalant Use | 239 of 2,324 224 of 2,358 | 0.8 points -0.9 to 2.5 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported Lifetime Alcohol Use | 1,288 of 2,324 1,236 of 2,358 | 3.0 points 0.1 to 5.9 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported 30-day Use of Alcohol | 332 of 2,324 330 of 2,358 | 0.3 points -1.7 to 2.3 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported Lifetime Marijuana Use | 265 of 2,324 238 of 2,358 | 1.3 points -0.5 to 3.1 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported 30-day Use of Cigarettes | 144 of 2,324 130 of 2,358 | 0.7 points -0.7 to 2.0 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported 30-day Marijuana Use | 116 of 2,324 130 of 2,358 | -0.5 points -1.8 to 0.8 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Treatment Group vs Control Group: Self-reported Lifetime Cigarette Use | 544 of 2,324 439 of 2,358 | 4.8 points 2.5 to 7.1 | 4,682 | NCT00650585 An Effectiveness Trial of Project ALERT |
| Colchicine vs Colchicine Placebo: deaths from any cause | 41 of 2,330 44 of 2,346 | -0.1 points -0.9 to 0.7 | 4,676 | NCT02551094 Colchicine Cardiovascular Outcomes Trial (COLCOT) |
| Colchicine vs Colchicine Placebo: serious adverse events | 383 of 2,330 404 of 2,346 | -0.8 points -2.9 to 1.4 | 4,676 | NCT02551094 Colchicine Cardiovascular Outcomes Trial (COLCOT) |
| Interactive Two-way SMS Dialogue vs No SMS Control: Thermal Care | 2,245 of 2,332 2,232 of 2,343 | 1.0 points -0.2 to 2.2 | 4,675 | NCT04598165 Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support |
| SMC021 vs Placebo: Number of Patients With Non-vertebral Fractures | 75 of 2,334 82 of 2,331 | -0.3 points -1.4 to 0.7 | 4,665 | NCT00525798 A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D |
| SMC021 vs Placebo: serious adverse events | 340 of 2,334 378 of 2,331 | -1.6 points -3.7 to 0.4 | 4,665 | NCT00525798 A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D |
| Exemestane vs Tamoxifen: serious adverse events | 383 of 2,320 439 of 2,338 | -2.3 points -4.5 to -0.1 | 4,658 | NCT00038467 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer |
| Survive at Day 28 vs Non-survive at Day 28: serious adverse events | 1,070 of 4,010 519 of 642 | -54.2 points -57.3 to -50.6 | 4,652 | NCT01354197 The Thai Surgical Intensive Care Study (Thai-SICU Study) |
| FluBlok (Lots A, B, C) vs Placebo: Number of Participants Reporting Unsolicited Adverse Events | 61 of 2,344 67 of 2,304 | -0.3 points -1.3 to 0.6 | 4,648 | NCT00539981 Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok |
| FluBlok (Lots A, B, C) vs Placebo: deaths from any cause | 1 of 2,344 1 of 2,304 | -0.0 points -0.2 to 0.2 | 4,648 | NCT00539981 Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok |
| FluBlok (Lots A, B, C) vs Placebo: serious adverse events | 30 of 2,344 34 of 2,304 | -0.2 points -0.9 to 0.5 | 4,648 | NCT00539981 Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok |
| Dronedarone 400mg Bid vs Placebo: Cardiovascular Death | 65 of 2,301 94 of 2,327 | -1.2 points -2.3 to -0.2 | 4,628 | NCT00174785 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
| Dronedarone 400mg Bid vs Placebo: First Hospitalization for Cardiovascular Reason or Death From Any Cause | 734 of 2,301 917 of 2,327 | -7.5 points -10.2 to -4.8 | 4,628 | NCT00174785 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
Code
curl "https://conductscience.org/api/comparisons/v1?page=96"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=96
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00650585-01ee93ef",
"title": "Treatment Group vs Control Group: Self-reported Lifetime Inhalant Use",
"summary": "379 of 2324 against 342 of 2358; risk difference 1.8 points, 95% interval -0.3 to 3.9; NCT00650585, An Effectiveness Trial of Project ALERT",
"record": "/library/comparisons/NCT00650585-01ee93ef",
"nct_id": "NCT00650585",
"kind": "outcome",
"participants": 4682,
"risk_difference": {
"value": 0.018042727069674552,
"lower": -0.002643350176353601,
"upper": 0.03874272744341799
},
"group_1": "379 of 2,324",
"group_2": "342 of 2,358",
"difference": "1.8 points",
"interval": "-0.3 to 3.9",
"trial_title": "An Effectiveness Trial of Project ALERT"
},
{
"id": "NCT00650585-067c3337",
"title": "Treatment Group vs Control Group: Self-reported 30-day Inhalant Use",
"summary": "239 of 2324 against 224 of 2358; risk difference 0.8 points, 95% interval -0.9 to 2.5; NCT00650585, An Effectiveness Trial of Project ALERT",
"record": "/library/comparisons/NCT00650585-067c3337",
"nct_id": "NCT00650585",
"kind": "outcome",
"participants": 4682,
"risk_difference": {
"value": 0.007844172035287644,
"lower": -0.009279461854693999,
"upper": 0.025002466147200766
},
"group_1": "239 of 2,324",
"group_2": "224 of 2,358",
"difference": "0.8 points",
"interval": "-0.9 to 2.5",
"trial_title": "An Effectiveness Trial of Project ALERT"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=97",
"request_id": "r_zAi4Jx45GUERV-"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant